An interview with Bayer's Bernardo Kanahuati, senior vice president, global head cardiorenal and product team lead, Kerendia, and Katja Rohwedder, senior medical affairs physician, global medical ...

Berlin: Bayer has announced the submission of a marketing authorization application to the European Medicines Agency (EMA), ...

Bayer seeks European marketing approval for use of finerenone in adult patients with HF with a left ventricular ejection fraction (LVEF) of =40%: Berlin Tuesday, February 4, 2025, ...

Bayer has filed its mineralocorticoid receptor antagonist (MRA) finerenone as a treatment for a common form of heart failure ...

Finerenone treatment vs placebo was associated with a reduced risk for new-onset diabetes by 24% among patients with HFmrEF or HFpEF.

January saw almost every major cardiovascular subspecialty represented among our most-clicked stories of the month.

Kerendia (Finerenone) is a non-steroidal, selective mineralocorticoid receptor antagonist developed by Bayer HealthCare Pharmaceuticals. It is used in the treatment of chronic heart failure with ...

Foul by Aleksandar Pavlovic (FC Bayern München). Goal! Feyenoord 3, FC Bayern München 0. Ayase Ueda (Feyenoord) left footed shot from the centre of the box to the bottom right corner. Assisted ...

Vincent Kompany's Bayern Munich head to Rotterdam on Wednesday as they face a tricky UCL league stage clash against Feyenoord. Bayern find themselves in 12th in the standing ahead of today's ...